4,215 Shares in Zoetis Inc. $ZTS Purchased by Narwhal Capital Management

Narwhal Capital Management purchased a new position in Zoetis Inc. (NYSE:ZTS) in the second quarter, Holdings Channel reports. The fund purchased 4,215 shares of the company’s stock, valued at approximately $657,000.

Other large investors also recently bought and sold shares of the company. Nova Wealth Management Inc. acquired a new position in shares of Zoetis during the first quarter valued at approximately $25,000. 1248 Management LLC acquired a new position in shares of Zoetis during the first quarter valued at approximately $27,000. Saudi Central Bank acquired a new position in shares of Zoetis during the first quarter valued at approximately $29,000. REAP Financial Group LLC raised its holdings in shares of Zoetis by 201.5% during the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after acquiring an additional 131 shares during the last quarter. Finally, Cornerstone Planning Group LLC raised its holdings in shares of Zoetis by 79.3% during the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock valued at $30,000 after acquiring an additional 88 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analyst Upgrades and Downgrades

ZTS has been the subject of a number of research analyst reports. Argus reissued a “buy” rating and set a $190.00 target price on shares of Zoetis in a report on Tuesday, September 9th. Piper Sandler increased their target price on Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Stifel Nicolaus cut Zoetis from a “buy” rating to a “hold” rating and reduced their target price for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Weiss Ratings reissued a “hold (c-)” rating on shares of Zoetis in a report on Wednesday. Finally, Leerink Partnrs cut Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Five research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Zoetis currently has an average rating of “Moderate Buy” and a consensus price target of $200.88.

Zoetis Price Performance

NYSE:ZTS opened at $143.61 on Thursday. Zoetis Inc. has a one year low of $139.34 and a one year high of $196.55. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. The stock has a market cap of $63.65 billion, a PE ratio of 24.72, a P/E/G ratio of 2.29 and a beta of 0.90. The stock has a 50 day moving average price of $149.41 and a 200 day moving average price of $154.74.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.14. The company had revenue of $2.46 billion during the quarter, compared to analyst estimates of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same period in the prior year, the business posted $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities research analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.